A series of myelographies performed with a smaller than customary dose (3.75 g) of metrizamide was compared with a series using the larger customary dose. While little decrease in the incidence of headache and vomiting resulted from the decreased dose, there was a heartening drop in the incidence of psychoneurologic side effects . Little difference in diagnostic quality between the two series resulted when the contrast agent was injected close to the site of main interest, but total spinal canal myelography performed with the low dose is often inadequate.
Metrizamide has become the contrast agent of choice for lumbar myelography because it is simple to use, provides superior anatomic definition , may be used in conjunction with computed tomography (Gl), and does not cause arachnoiditi s [1 -5] . However, many are reluctant to use metrizamide for cervical or total myelography because of justifiable con cern over acute to xic effects, suc h as headache , vomiting , mental and neurologic disorders, and seizures. Sin ce a correlation between complications and the total dose of metrizamid e has been established [1 , 6] , we have been interested in determining if the side effects of metrizamide mye lography can be significantly reduced by using dosages below those customarily employed without sacrificing diagnostic information .
Subjects, Methods, and Results
Metrizamide , as distributed in North Am eri ca , is pack aged in two dosages. Th e larg er package , hereafter ca ll ed the larg e dose, is intended to be used for mye lograph y and contains 6 .75 g metrizamide (3 .26 g I). Wh en reconstituted , thi s yield s 10.9 ml (at 3 00 mg Il ml) to 19.2 ml (at 170 mg Il ml) of contrast mediurn . Th e small er pac kage, w hi c h we w ill call the small dose, is intended to be used prim arily for me trizamide CT examinati on, and contains 3 .7 5 g metrizamid e (1 .81 g I). Th e volume of contrast medium avail abl e after reconstitution of thi s small dose vari es from 6 ml (300 mg Il ml) to 10. 6 ml (1 70 mg I/ ml) . In this study , myelography was perform ed using either th e small dose , in whi c h case all was generally used , or the large dose , in whi c h case at least three-fourths o f th e to tal avail able dose was used . Of th e 290 ce rvi ca l and l or lumbar mye lograms in c lu ded in thi s study, 13 7 were obtain ed with th e larg e dose and 153 with th e small dose.
Assignment of pati ents to th e two groups was not arbitrary, sin ce we did not wish to compromise the quality of studi es. Th e large d ose was generall y selected wh en pati ents were large , obese, and had unfavorabl e spin al c urvatures o r suspec ted larg e spin al ca nals , and when total spin al myelograph y was needed . Th e small d ose was selected for small pati ents, c hild re n, and fo r th ose in wh om onl y one reg ion o f th e spinal ca nal was of c lin ical interest. As th e study progressed, it became app aren t th at th e small dose was adeq uate for most pati ents oth er th an larg e persons nee ding total spin al mye log raphy , and th e relati ve use of th e two dosa ges shifted . All mye log raphi es term ed lumba r we re perform ed by lumbar injection, and th e contrast materi al was no t run above the thoracic reg ion. Most small-d ose c ervical studi es perform ed by lateral CI-C2 pun ctures , whil e over half of the large-dose ce rvi ca l studi es were perform ed by a lumbar injecti on of th e metrizami de . Typ ical conce ntration s and vo lum es o f metri za mi de used for th e low-dose stu d ies we re 190 mg Il ml (9 .5 
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20 0 ml) for th e usual lumbar myelogram and 220 mg Il ml (8 .2 ml) for th e usual ce rvi ca l study . Pati ents were c hec ked for 48 hr after myelography , and all symptoms and neurologic signs were recorded (tables 1 and 2). Tabl e 2 li sts th e numbers of patients in whom eac h specific symptom or sign occurred . Since more th an one sig n or symptom occurred in some of th e patents , the total number of patients having side effec ts was not th e same as the sum of th e col umns of individual side effec ts. Th e percentage of patients having mental or neurolog ic side effec ts in eac h group is noted in tabl e 1 .
Th e studies were graded as to quality. Th e good studies were those in whi c h all anatomi c details, in c luding spin al cord , nerve roots , and nerve root sleeves were clearly visible. Adequate studies were those in which some small anatomi c details were not c lear, A B
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-Cervical myelogram using 8 .2 ml of 220 mg Il ml metrizamid e. Lateral (A) and obliqu e (B) views show typically adequate filling obtained from small dose injected at Cl-C2 .
but pathology was not likely to be obscured. Poo r studies were those in which the conce ntration of co ntrast medium was so low th at significant pathol ogy co uld not be ruled out. Th ere was little difference between the quality of large-and small-dose studies when only the cervical or lumbar region was studied by injec tion of metrizamide into that reg ion, but large-dose studies were c learly superior to small when the site of injection was remote from the site of interest (table 3) . The large-dose studies were generally more esthetically pleasing because larg er segments of th e spinal canal would be filled at one tim e and th e concentrations were often higher, but c loser in specti on generally revealed th at th e same anatomic details were present in both . Th e small dose of contrast medium was generally adeq uate to fill th e cervical spinal canal, so th at filming tec hniques for large-and small-dose ce rvi cal studies were similar ( fig . 1 ). For th e lumbar studi es, the smaller portion of th e lumbar canal fill ed by th e low-dose volume increased th e importance of using horizontal-beam oblique filming to demonstrate nerve root sleeve filling ( fig . 2 ).
Discussion
It has been interesting to observe the wide variety of techniques proposed for metrizamide myelography and the vari ed experiences with postmyelographic complications. Early Scandinavian investigators used c onservative techniques, keeping both the total dose and concentration low and avoiding unnecessary bathing of the spinal cord with metrizamide . Th ey were no doubt influenced by their prior experiences with more to xic water-soluble myelographic agents such as meglumine iothalamate (Conray), meglumine iocarmate (Dimer X), and methiodal sodium [4, 7 , 8] . Using conservative methods , they experienced a low incidence of postmyelographic side effects. In a series of 4,568 lumbar myelographies reported to Nyegaard and Co . before 1976, the incidence of headaches was only 32 %, only 7% of patients had vomited, and only one seizure had occurred, and that in a known epileptic [9] . The concentration of metrizamide used in most of these cases was only 170 mg Il ml , and the average dose was 1.87 g I, nearly the same as that used in the small-dose examinations in our study. At the same time, 1 ,232 cervical myelographi es were reported [10] . Headache occurred in 37 %, vomiting in 14%, and seizures in 0 .6% (eight patients). Average dose for cervical studies was 2.5 g I. Similar low incidences of side effects were reported in other articles , with the side effects of cervical myelography [11] being greater than those of lumbar myelography [2, 7 , 8] . Skalpe and Amundsen [11] encountered no seizures in their first thousand myelograms, and only 17 seizures were found among the first 40 ,000 examinations compiled by Nyegaard and Co . [12] .
American users of metrizamide have reported more side effects. Using most or all of the large dose of metrizamide (2 .5-3.2 g I), Sackett et al. [1 3 ] noted headaches in 57 % and nausea in 39% of the patients. They attributed th ese higher incidences to the inclusion of man y cervi cal and thoracic studies. Baker et al. [12] noted headaches in 62 % and nausea and vomiting in 38 % of their myelograms, and observed that th ey had used a high er mean dose (2.69 g I) of metrizamide th an had been used in various Scandinavian series [12] . The in c id ence of seizures also increased in the reported American ex peri ence . Sackett et al. [13] had three seizures in 215 patients, and Kieffer et al. [14] noted seizures in two patients, each of whom received 4 .2 g I, in a series of 117 myelograms. In a se ri es from the Neth erl and s, cervical myelography, using very high doses of metrizamid e (4 .5-5 .5 g I) , resulted in one se izure in 16 patients [1 5] .
Concern has rec ently developed over mental disorders rel ated to the neurotoxic ity of metrizamid e. These disorders range from subtl e psychoorganic sy ndrom es co nsisting of impaired memory and depression to cases of psyc hosis. In a series of 18 lumbar myelograms obtained with a small dose of metrizamide (1 .8 g I), Ri c kert et al. [16] found shortterm memory deficits and depression in six pati ents. These findings were mild and probably would not have bee n detected without the extensive neurologi c , psyc hiatri c, and psychomotor te sting th ey employed . In a se rie s of 75 patients who had rece ived various amounts of metrizamide for cervical, thoracic , or lumbar myelography , Schm idt [6] noted a profound organic psychosis in seven and visual hallucin ation s or illusions in three. The frequency of mental disorders was higher after cervical myelography , in old er patients , and when larger amounts of metrizamide were used. Using still higher doses of metrizam id e (4 .5 -5.5 g I), Gelmers [15] found 12 of 16 patients who had cervical myelograms experienced ac ute psychoorganic reactions, with clouding of conscio usness, difficulty paying attention , disordered perceptions , and anxiety or panic states. These disorders lasted 3 -5 days. Psychoorgani c reactions did not follow lumbar or thoracic myelograms performed with small doses (1.8-3 g I) [15] . Haug e and Falkenberg [17] , in their recently published seri es, reported the unusual finding of a higher incidence of postmyelographic ce rebral side effects after lumbar (46 % ) than after cervical (25 % ) myelograms.
In our series, we fo u' nd that dizziness, agitation, and disorientation occurred more often after large-dose ce rvi cal myelograms than after small , and more often after larg edose lumbar studies th an after small-dose cervi cal stud ies (table 2) . Objective neurolog ic sig ns were o nl y found in the high-dose studies (table 3) . Thi s co rrelati o n of mental and neurologic disorders with dose levels was the most interesting finding in this se ries . Whil e we had hoped for a signifi cant reduction in the incidence of headac he and vOJTl iting using a smaller dose , the differences were not impressive (tabl e 1). However, th e comments of referring physic ians rega rding postmyelographic patient discomfort decreased significantly after adoption of lower-dose studies, perhaps refl ecting a change in severity of the postmyelographic symptoms. No seizures occurred in these patients , and non e had occurred in the metrizamide myelographic patients preceding them at the UCLA Medical Center. No premed ication has been used in an attempt to prevent se izures.
Wh en using relatively low doses of metrizamid e for myelography, it is necessa ry to pay c lose attenti o n to suc h details of radiographi c technique as low ki lovoltage, optim al film-sc ree n co mbination s, small focal spots, and tig ht coning . As several authors have emph asized [1 , 2 , 18] . horizo n-tal-beam filming is very important. This is particularly true in low-dose lumbar myelograms, for it enables one to fill multipl e nerve root sleeves with a relatively low volume of contrast medium. Metrizamide must be injected slowly to avoid excessive dilution , and injection into the cervical region should be done in the prone position to promote pooling of contrast medi um . Cervical myelography is generally perform ed by C1-C2 injections , as preferred by early investigators [11] , since good studies may be obtained using lESS contrast agent than is needed for lumbar injection techniques [19 , 20] . An exception is made in cases in which pl ain film findings and clinical evidence of myelopathy suggest the possibility of a cervical block, in which case metrizamide is injected first into the lumbar canal to avoid trapping contrast material in the high cervical region . After having tried most of the described methods for performing metrizamide myelography, we now generally use small-dose technique for routine lumbar or cervical myelography. When it is necessary to obtain good filling of the entire canal or both the cervical and lumbar regions , we generally use large doses except in small patients and children. Alternatively , a small dose may be used with the option of examining a region remote from the injection site with CT if the concentration of metrizamide proves to be too low for standard myelographi c technique .
